Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …

Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …

Streptococcus pneumoniae has a complex relationship with its obligate human host. On the
one hand, the pneumococci are highly adapted commensals, and their main reservoir on the …

Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …

Rationale: The immunological and protective role of pneumococcal carriage in healthy adults
is not known, but high rates of disease and death in the elderly are associated with low …

Respiratory mucosal immunity induced by vaccination is vital for protection from coronavirus
infection in animal models. In humans, the capacity of peripheral vaccination to generate …

Colonization of the upper respiratory tract by pneumococcus is important both as a determinant
of disease and for transmission into the population. The immunological mechanisms that …

Controlled human infection (CHI) trials, in which healthy volunteers are experimentally infected,
can accelerate the development of novel drugs and vaccines for infectious diseases of …